Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 1
2009 1
2010 2
2011 3
2012 8
2013 7
2014 19
2015 16
2016 11
2017 15
2018 23
2019 21
2020 33
2021 23
2022 35
2023 26
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
Breast cancer: Biology, biomarkers, and treatments.
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Barzaman K, et al. Among authors: kazemi mh. Int Immunopharmacol. 2020 Jul;84:106535. doi: 10.1016/j.intimp.2020.106535. Epub 2020 Apr 29. Int Immunopharmacol. 2020. PMID: 32361569 Review.
Breast cancer immunotherapy: Current and novel approaches.
Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Barzaman K, et al. Among authors: kazemi mh. Int Immunopharmacol. 2021 Sep;98:107886. doi: 10.1016/j.intimp.2021.107886. Epub 2021 Jun 19. Int Immunopharmacol. 2021. PMID: 34153663 Review.
CD25 gene polymorphism and multiple sclerosis.
Alsahebfosoul F, Salehi R, Ghaffari S, Jahanbani-Ardakani H, Etemadifar M, Kazemi M, Abtahi SH. Alsahebfosoul F, et al. Among authors: kazemi m. Mult Scler Relat Disord. 2017 Nov;18:117-118. doi: 10.1016/j.msard.2017.09.005. Epub 2017 Sep 20. Mult Scler Relat Disord. 2017. PMID: 29141792 No abstract available.
Immunotherapies targeting tumor vasculature: challenges and opportunities.
Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R. Dianat-Moghadam H, et al. Among authors: kazemi m. Front Immunol. 2023 Sep 1;14:1226360. doi: 10.3389/fimmu.2023.1226360. eCollection 2023. Front Immunol. 2023. PMID: 37727791 Free PMC article. Review.
Oncolytic virotherapy in hematopoietic stem cell transplantation.
Kazemi MH, Kuhestani Dehaghi B, Roshandel E, Parkhideh S, Mehdizadeh M, Salimi M, Hajifathali A, Hamidpour M. Kazemi MH, et al. Hum Immunol. 2021 Sep;82(9):640-648. doi: 10.1016/j.humimm.2021.05.007. Epub 2021 Jun 9. Hum Immunol. 2021. PMID: 34119352 Review.
Lip Reconstruction after Tumor Ablation.
Ebrahimi A, Kalantar Motamedi MH, Ebrahimi A, Kazemi M, Shams A, Hashemzadeh H. Ebrahimi A, et al. Among authors: kazemi m. World J Plast Surg. 2016 Jan;5(1):15-25. World J Plast Surg. 2016. PMID: 27308236 Free PMC article. Review.
CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, Yousefi M, Jadidi-Niaragh F. Ghalamfarsa G, et al. Among authors: kazemi mh. Expert Opin Ther Targets. 2019 Feb;23(2):127-142. doi: 10.1080/14728222.2019.1559829. Epub 2018 Dec 26. Expert Opin Ther Targets. 2019. PMID: 30556751 Review.
222 results